The glycocalyx is a layer of glycoconjugates found on the surface of both host cells and microorganisms. Information presented on some of the glycans on glycoconjugates is recognized by mammalian glycan-binding proteins, lectins, and these interactions modulate various physiological processes, including host innate immune responses. Lectins and host glycoconjugates are synthesized in the same secretory pathway. One notable exception is a family of soluble β-galactoside-binding lectins, galectins, which are synthesized and accumulated in the cytosol and thereby segregated from their glycan ligands. In cases where pathogenic infection persists and tissue injury occurs, galectins are passively released from injured cells. In addition, galectins are actively secreted through unconventional secretory pathways by inflammation-activated or differentiating cells. Thus, extracellular emergence of galectins is associated with the presence of pathogenic hazards. Evidence from a series of studies suggests that galectins exert multiple immunological effects. Extracellular galectin-3 acts as a damage-associated molecular pattern (DAMP) and adhesion molecule for neutrophils in lungs to initiate a proinflammatory response and to mediate rapid neutrophil migration in lungs infected with pathogenic microorganisms. In this review, the roles of galectin-3 in initial innate immune responses and resolution are discussed together with a historical overview of research on galectins in the secretory pathway and innate immunology.
A. Galectins Accumulate in the Cytosol: Distinct Segregation from Glycan Ligands
In mammalian cells, the majority of glycans, i.e., oligosaccharides and polysaccharides, are covalently linked to either proteins (glycoproteins) or lipids (glycolipids). Those glycoconjugates are synthesized in the lumen of the secretory pathway consisting of the endoplasmic reticulum and Golgi apparatus and subsequently either transported into intracellular organelles, such as lysosomes or the cell surface, where they become surface-associated glycoconjugates or are released into the extracellular space (secreted proteins). Consequently, most complex oligosaccharides are located either in the lumen of the secretory pathway, on the cell surface or in the extracellular space. The biological information of oligosaccharides is decoded by glycan-binding proteins, lectins, for performing extrinsic functions, propounding the theory that lectins should be present in similar locations as glycoconjugates (1) . All mammalian lectins are synthesized in and transported through the secretory pathway, with the unique exception of galectins.
Galectins are soluble, non-glycosylated lectins defined by a conserved carbohydrate recognition domain (CRD) that shows affinity for β-galactoside, especially glycans containing a number of lactosamine residues (Galβ1-4GlcNAc) (2) (3) (4) . Detailed information on the carbohydrate binding specificity of galectins has been provided in the review by the group of Hirabayashi in the TIGG special issue 'Galectins updated' (5) . In humans, 11 galectins have been identified to date (2) . These proteins exhibit structural differences in the presentation of CRD (Fig. 1A) . Some contain one CRD (prototype) and exist as either monomers or dimers while others (tandem repeats) contain two CRDs connected by a short linker region. Galectin-3 uniquely occurs as a chimeric protein with one CRD at the C-terminus and an additional non-CRD domain at the N-terminus, which is involved in its oligomerization.
Upon binding to its glycan ligands, the conformation of galectin-3 appears altered. Subsequently, galectin-3 molecules oligomerize through self-assembly of the non-CRD domains and become multivalent in glycan binding (Fig. 1B) (6) (7) (8) (9) (10) (11) (12) . In addition to N-terminal-mediated oligomerization, CRD of galectin-3 selfassociates upon binding to its ligands, thereby contributing to positive cooperativity in the formation of multivalency (8, 11, (13) (14) (15) . Galectins do not contain a signal sequence for transport to the secretory pathway and are synthesized by free ribosomes. Consequently, these proteins initially accumulate in the cytosol where there are very few glycoconjugates (Fig. 2) . In cases where galectins function as lectins by binding to glycans, they are required to translocate to the extracellular space where glycoconjugates are present. This scenario is one of the topics discussed in this review.
Alternatively, glycoconjugates can translocate to the cytosol where galectins accumulate. Indeed, when pathogens, unnatural aggregates of proteins or chemicals within endosomes or phagosomes cause damage to the vesicle membrane, glycoconjugates normally restricted to the luminal face of vesicles are ectopically exposed to the cytosol and subsequently recognized by cytosolic galectins (Fig. 2) . This recognition is part of the process of activating cellautonomous immunity against intracellular hazards (pathogens or crystals, such as monosodium urate) and induces autophagy and a dynamin-like guanylate-binding protein-regulated antimicrobial response (19, 20) . Researchers interested in the immunological significance of recognition of internal damage by galectins are encouraged to read the review by Liu and co-workers in this TIGG special issue, Galectins updated (21) .
Interactions between glycoconjugates and lectins are regulated by the expression of lectin and biosynthesis of its glycan ligands. Cytosolic segregation is an additional way to regulate the functions of galectins. The importance of segregation of cytosolic protein from its receptor to regulate activity has been demonstrated for another cytoplasmic protein, basic fibroblast growth factor (bFGF) devoid of a signal sequence. Expression of a bFGF variant containing a signal sequence resulted in autocrine transformation into highly tumorigenic cells, supporting the biological significance of cytosolic localization as a pathway for regulating activity (22, 23) .
Here, the biological significance of the unique location of galectins is discussed with a specific focus on its roles in the innate immune response at the initial stage of infection. To avoid any redundancy in the TIGG galectin special issue, I do not intend to completely cover the proposed functions of galectin-3 in innate immunity and host-pathogen interactions, which has been extensively explored and reviewed over several years (18, (24) (25) (26) (27) (28) . Instead, the focus of the current review is on the interactions between galec- 
B. Release of Galectins into Extracellular Space
Cytosolic galectins are released via two pathways; (i) cell necrosis (passive release) and (ii) active secretion by live cells through a unique pathway known as the leaderless, unconventional or alternative secretory pathway (Fig. 2 , Release or Secretion).
The former mechanism is observed in lesions of infections ( Fig.   2) (32-34) . The immunological significance of passive release of galectins will be discussed in the following section. The latter pathway is known as regulatory secretion in a number of cell types, such as polarized epithelial cells, differentiating muscle cells, myoblasts and M2 macrophages (35) (36) (37) (38) (39) (40) . While active secretion was observed at the time of discovery of galectins (41, 42) , the specific molecular mechanism underlying this unconventional type of secretion remains a topic of controversy (43) . In 1999, Hughes published a comprehensive review on secretion processes of galectins based on the available findings at the time and proposed the involvement of four pathways: (i) direct translocation across the plasma membrane (Fig. 3A) , (ii) export via intracellular vesicles (Fig. 3B ), (iii) autophagic internalization following by release as exosomes (Fig. 3C) , and (iv) export though blebbing-ectosomes ( Fig. 3D) (44) . Between 1999 and 2018, many studies have published evidence supporting the different pathways proposed by Hughes (43, (45) (46) (47) although the specific mechanisms of secretion remain elusive. Pioneering work on galectin-1 secretion using muscle differentiation systems was documented in 1990 (39) .
Upon induction of differentiation, myoblasts start to make contact with neighboring myoblasts and subsequently fuse together to form myotubes. During the myogenesis process, galectin-1 is highly concentrated just beneath the membrane into patch-like structures and released as galectin-1-rich microvesicles, designated ectosomes ( Fig. 3D ). Similar to galectin-1, we observed that galectin-3 forms patch-like structures located adjacent to the plasma membrane in BHK cells (36) , differentiating myoblasts and nascent myotubes, and is actively secreted from these cells (48) 2) . Inter- Thus, regulation of galectin secretion appears to be one of the critical parameters in myogenesis. Hughes and co-workers additionally demonstrated that release of galectin-3 through the ectosome pathway is augmented when the protein is artificially acylated and concentrated just beneath the plasma membrane (52) (Fig. 3D ).
2) Ann Rancourt and Sachiko Sato, Unpublished results.
Concentrated galectin-3 is pinched off as ectosomes and slowly released into the extracellular space (Fig. 3D ). In contrast, experiments by other groups using non-differentiated cells, such as CHO and HeLa, have suggested that secretion of galectins is independent of microvesicles (53, 54) . Interestingly, upon recognition of β -glucan, the major component of fungal cell walls, by the C-type lectin, dectin-1, macrophages secrete galectin-3 in a manner dependent on inflammasome activity and an active autophagic process, indicating release through the autophagic pathway ( 
C. Passive Release of Galectin-3 from Cells Residing at the Lesion of Infection
Galectins are also passively released from cells when surface integrity is compromised (Fig. 2) . For example, upon induction of cellular injury by either a pathogenic microorganism or initial inflammation triggered by the infection, galectins directly translocate 
E. Roles of Galectin-3 as a DAMP and Adhesion Molecule in Neutrophil Migration
Determination of the roles of cytosolic galectins in vivo using mouse models lacking galectins has been a subject of research focus since the group of Françoise Poirier first established galectin-1
and -3 null mouse lines in 1993 and 1998, respectively (97, 98) .
Using galectin-3 null mice, her group was the first to demonstrate an in vivo role of galectin-3 in inflammation. They observed impairment of thioglycolate-induced neutrophil recruitment into the peritoneal cavity at the chronic inflammation stage in galectin-3 null mice while acute neutrophil migration was not affected (99) .
Notably, neutrophil recruitment in chronic but not acute peritoneal inflammation is independent of β 2 -integrins (100, 101) and galectin-3 is actively secreted from macrophages that migrate at the late stage of thioglycolate-induced inflammation (38) . The results support a role of galectin-3 in integrin-independent neutrophil migration in peritoneal chronic inflammation.
In lungs, the majority of neutrophils are physically seques- In addition, the concentration of galectin-3 is found at the place where neutrophils bind to the tricellular corners of endothelial cells, strongly raising the possibility that galectin-3 facilitates S.
pneumoniae-induced neutrophil migration as an adhesion molecule in lung (7, 34, 107) . Recent research on tularemia, a type of pulmonary acute infection-induced sepsis caused by Francisella, suggests that pulmonary infection triggers galectin-3 release and neutrophil migration is significantly reduced in galectin-3-null mice (108) . The mechanism by which galectin-3 induces neutrophil migration in lungs warrants further investigation with the aid of pulmonary intravital microscopy to visualize integrin-independent neutrophil migration in vivo (109, 110) .
Lack of galectin-3 also impairs neutrophil migration induced by infection with protozoan parasite Leishmania major (substrain LV39) in both air pouch and footpads (32, 111) . Due to the lack of initial neutrophil migration, pathogenesis is initially aggravated. induces both cytokine responses and neutrophil migration (32, 113) further supports its role as a DAMP.
F. Role of Galectin-3 in Neutrophil Functions in vitro
During migration from the circulation, the state of neutrophils is altered from naïve to primed by cytokines and chemokines pre- shedding, CXCL8 (IL-8), which can further attract neutrophils to the site, and ROS production in primed neutrophils (115) (116) (117) , and this action is partly mediated through cross-linking with CD66 (118, 119) . Extracellular galectin-3 also increases phagocytosis of Candida albicans hyphae and C. parapsilosis yeast (120, 121) .
During migration towards bacteria-derived chemoattractants, neutrophils are nonresponsive to the same agonist (desensitization).
Galectin-3 is able to break this desensitized status by inducing ROS-mediated inactivation of the chemoattractant (122) . Consequently, galectin-3 stimulates the defense mechanism of neutrophils at the site of infection.
Although swift neutrophil recruitment to an infected lesion is critical to eliminate pathogens and keep infection at bay, these cells could also cause serious damage to host tissues due to release of ROS and protease into extracellular spaces. Thus, the clearance of neutrophils that are recruited to the lesions is also critical to minimize collateral damage at the site of infection. As part of the mechanism of resolution of inflammation, apoptotic neutrophils are glycan binding domain inside its CRD, leading to the proposal that cleavage of galectin-3 is a termination system for galectin-
3-induced inflammation (15).

G. Perspectives
Cytosolic for UDP-GlcNAc are ~10-fold higher than the concentration in the lumen of Golgi apparatus, and thereby the reactions mediated by these enzymes are not optimal. Thus, the intracellular concentration of UDP-GlcNAc, which is affected by the extracellular concentration of glucose, glucosamine and GlcNAc, presents another regulatory mechanism to control the activity of galectin-3. Accordingly, during the course of infection/inflammation, the functions of galectin-3 are constantly regulated by at least three independent parameters (availability of galectin-3 for glycan recognition, cleavage of galectin-3 and intracellular UDP-GlcNAc concentrations) in a spatiotemporal, context-dependent and tissue-specific manner.
